| abstract |
DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity n n n n n n n n n n wherein, for example, n Ring A is optionally substituted 2,6-pyrazindiyl; n X is ═O; n Ring B is optionally substituted 1,4-phenylene; n Y 1 is a direct bond or —O—; n Y 2 is —(CH 2 ) r — wherein r is 2 or 3; n n is 0 or n is 1 when Y 1 is a direct bond between Ring B and Ring C and when Ring B is 1,4-phenylene and Ring C is (4-6C)cycloalkane; n Ring C is optionally substituted (4-6C)cycloalkane, (7-10C)bicycloalkane, (8-12C)tricycloalkane, phenylene or pryidindiyl; n L is a direct bond or —O—; n p is 0, 1 or 2 and when p is 1 or 2 R A1 and R A2 are each independently hydrogen or (1-4C)alkyl; n Z is carboxy or a mimic or bioisostere thereof. |